ProShares Ultra Nasdaq Biotechnology

S000018718ProShares TrustCIK 0001174610

Share classes

1 class of this one portfolio · 1 exchange-listed

Class ID	Symbol	Status	Security in the master	Type
C000051848	BIB	LINKEDSEC_TICKER	BIBProShares Ultra NASDAQ Biotechnology	ETF

The share-class bridge is a snapshot, not history. The SEC's fund share-class file says what each class trades as today, not what it traded as at a past report date. A fund that changed ticker or converted from a mutual fund resolves to its present-day symbol for every historical month shown.

Share classes

Report period

1 period filed. Holdings below describe the selected month only.

2026-02-28

Filing

NPORT-P · filed 2026-04-24

Report date: 2026-02-28
Net assets: $91,710,153.27
Total assets: $95,192,396.54
Total liabilities: $3,482,243.27
Assets invested: $0
Cash not reported in C or D: $9,533,496.23
Amendment: No
Accession: 0002071691-26-009265

By asset category

N-PORT Item C.4.a

ECEquity - common$61.88M73.7%

DEDerivative - equity$15.14M18.0%

RARepurchase agreement$5.22M6.2%

STIVShort-term investment veh…$1.66M2.0%

By asset category

By issuer category

N-PORT Item C.4.b

CORPCorporate$67.10M80.0%

OTHEROther; the filer describe…$15.14M18.0%

RFRegistered fund$1.66M2.0%

By issuer category

By investment country

as filed

USUS$75.40M90.2%

NLNL$1.35M1.6%

GBGB$1.26M1.5%

BMBM$929.4K1.1%

FRFR$925.2K1.1%

IEIE$826.8K1.0%

DKDK$741.4K0.9%

CHCH$739.1K0.9%

DEDE$514.7K0.6%

CACA$411.2K0.5%

KYKY$397.0K0.5%

SGSG$107.6K0.1%

By country

Classification look-through

Positions resolved to the master through ISIN, then rolled up through the taxonomy. 71.0% of reported value reaches a classification.

Equity · Health Care(246)$59.59M71.0%

Not resolved to the master(31)$24.31M29.0%

Equity · Materials(1)$4.2K0.0%

Classification covers part of the master. 5,771 of 13,106 active securities are classified. Anything unclassified is shown as its own band rather than dropped, so a look-through total that falls short of 100% is telling you about coverage, not about the fund.

Percentages are of the reported value of positions above ($83.90M), not of the fund’s net assets ($91.71M). The two differ by cash, derivatives filed with no market value, and rounding.

Classification look-through

Holdings

278 positions in this filing

Issuer nameAsset categoryIssuer categoryCountry

Issuer↕	In master	CUSIP / ISIN	Asset	Balance↕	Value↕	Weight▲	Country
Amylyx Pharmaceuticals, Inc.	AMLX	03237H101 US03237H1014	EC CORP	5,071 NS

151–200 of 278

← Prev4 / 6Next →

Balance is meaningless without its unit. N-PORT Item C.2.a says what the balance column counts: shares (NS), principal amount (PA), contracts (NC), or something the filer describes (OU). A bond position read as a share count is off by orders of magnitude. Every balance on this page carries its unit code.

Missing CUSIPs are filed as placeholders. Filers with no CUSIP conventionally write 999999999 or N/A rather than leaving the field blank — 1,187,114 of 5,347,869 positions do. Those are shown as missing here, not as identifiers.